These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32311895)

  • 21. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
    Song Y; Liu Z; Wang Q; Gao K; Wu T
    Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
    Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
    Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
    Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
    Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
    Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
    Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
    Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
    Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
    Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
    Front Immunol; 2022; 13():965932. PubMed ID: 36225940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.
    Wang Y; Xue YJ; Zuo YX; Jia YP; Lu AD; Zeng HM; Zhang LP
    Cancer Res Treat; 2024 Jul; 56(3):945-955. PubMed ID: 38351683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].
    Su Y; Bao S; Wei YP; Song LJ; Xue YM; Wei XD; Song YP; Yin QS
    Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):946-951. PubMed ID: 36709187
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficacy and safety of TBI+rATG-based conditioning regimen for haploidentical allogeneic hematopoietic stem cell transplantation in 11 cases of chemotherapy-resistant advanced peripheral T-cell lymphoma].
    Xu R; Li S; Liu HX; Wei DL; Jiang Y; Wang JJ; Liu SS; Wang C; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):578-581. PubMed ID: 37749039
    [No Abstract]   [Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
    Li Y; Li Y; Zhang M; Zhao H; Zhu M; Huang H; Hu Y
    Eur J Haematol; 2024 Jan; 112(1):94-101. PubMed ID: 37477866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
    Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
    Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.